- CEO
- Wook-Bin Im
- Full Time Employees
- 23
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Seoul South Korea
- IPO Date
- Mar 17, 2021
- Business
- BIODYNE Co., Ltd. is a South Korea-based medical biotechnology company specializing in the research, development, manufacturing, and commercialization of liquid-based cytology (LBC) systems, diagnostic reagents, and automated medical devices for cancer screening and cellular pathology diagnostics. Founded in 1999 and headquartered in Seoul, South Korea, the company operates within the in vitro diagnostics and medical devices industry, serving hospitals, pathology laboratories, screening clinics, and research institutions across domestic and international markets, including Asia, Europe, and the Americas. BIODYNE provides end-to-end cytology solutions organized across core product categories: automated liquid-based cytology preparation instruments, including the PATHPLORER series (such as PATHPLORER AUTO, PATHPLORER 4.7, PATHPLORER 4.63, and PATHPLORER ECO) and legacy Cellprep platforms, which utilize patented Blowing Technology to deposit diagnostic cells onto microscope slides in uniform monolayers via controlled air pressure; specialized cell preservation solutions and liquid-based reagents formulated for cell fixation, sample transport, and diagnostic staining for gynecological and non-gynecological testing; specialized cytology consumables, including sample preservation vials, membrane filters, coated glass slides, and transfer tips; and advanced cell collection devices, notably the EarlyPap self-sampling cervical collection brush developed with Bloom and Grip technology for speculum-free cytology and HPV/STD testing. In recent developments, BIODYNE transitioned into commercial revenue generation under its exclusive 20-year global technology licensing and supply partnership with Roche Diagnostics, which incorporates BIODYNE's proprietary Blowing Technology into the Roche VENTANA SP400 automated liquid-based cytology system. Following the launch of the VENTANA SP400 in Japan in 2025, BIODYNE commenced mass shipments of dedicated gynecological consumables and collected its final development milestone payment, establishing a recurring income structure based on instrument royalties and ongoing consumable supplies. In addition, the company has expanded production capabilities and pursued international regulatory certifications for its EarlyPap self-collection brush to support global cancer screening initiatives.